LONG-TERM TREND OF BLADDER CANCER MORTALITY IN SERBIA, 1991-2024: A JOINPOINT REGRESSION ANALYSIS

Keywords: bladder cancer, mortality, trends, joinpoint regression analysis

Abstract


Introduction/Aim: Bladder cancer is among the main urological diseases. Bladder cancer mortality trends vary significantly worldwide. This research sought to assess temporal trends in deaths due to bladder cancer in Serbia.

Methods: This was a population-based descriptive epidemiological study. Bladder cancer mortality data were obtained from an official database. Direct standardization with the World standard population was used to compute the age-standardized rates (ASRs) per 100,000. Joinpoint regression analysis was employed to assess temporal trends in bladder cancer mortality using the average annual percentage change (AAPC) alongside its 95% confidence interval (95% CI) over the 1991-2024 period.

Results: During the period 1991-2024, almost 20,000 deaths due to bladder cancer (about 15,000 among men and 5,000 among women) occurred in Serbia. Average annual ASR of mortality from bladder cancer was notably higher among males than females (5.94 versus 3.87 per 100,000, respectively). Significant increases in bladder cancer mortality trends were recorded for both males (AAPC=0.6%; 95% CI=0.4 to 0.9) and females (AAPC=1.3%; 95% CI=1.0 to 1.5). The male and female trends were not parallel, as the final selected model rejected parallelism (p = 0.008). A significant increase in bladder cancer mortality in women was recorded in middle age (age groups 55 to 69 years), while in men a more pronounced increase was observed in older people (age groups 70 and older).

Conclusion: An increase in bladder cancer mortality during more than three decades in Serbia implies that further analytical research is needed. 

References

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer; 2024. Available from: https://gco.iarc.who.int/today, accessed [27 September 2025].

Elmadani M, Klara S, Mustafa M, Kiptulon EK, Orsolya M. Global Burden of Rare Cancers: Insights from GLOBOCAN 2022 Estimates. Cancers. 2025;17(10):1721. doi: 10.3390/cancers17101721

Cogliano VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El Ghissassi F, et al. Preventable exposures associated with human cancers. J Natl Cancer Inst. 2011;103(24):1827-1839. doi: 10.1093/jnci/djr483

Jubber I, Ong S, Bukavina L, Black PC, Compérat E, Kamat AM, et al. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors. Eur Urol. 2023;84(2):176-190. doi: 10.1016/j.eururo.2023.03.029

Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of Bladder Cancer. Med Sci (Basel). 2020;8(1):15. doi: 10.3390/medsci8010015

Mossanen M, Nassar AH, Stokes SM, Martinez-Chanza N, Kumar V, Nuzzo PV, et al. Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes. Clin Genitourin Cancer. 2022;20(6):568-574. doi: 10.1016/j.clgc.2022.08.009

Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R, et l, editors (2021). Cancer Incidence in Five Continents, Vol. XI. IARC Scientific Publication No. 166. Lyon: International Agency for Research on Cancer. Available from: https://publications.iarc.fr/597.

Zhang Y, Rumgay H, Li M, Yu H, Pan H, Ni J. The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040. J Glob Health. 2023;13:04109. doi: 10.7189/jogh.13.04109

Statistical Office of the Republic of Serbia. Demographic yearbook in the Republic of Serbia, 1991-2024. Belgrade: Statistical Office of the Republic of Serbia; 2025. Available from: https://www.stat.gov.rs/en-us/ , accessed [27 September 2025].

Mathers CD, Fat DM, Inoue M, Rao C, Lopez AD. Counting the dead and what they died from: an assessment of the global status of cause of death data. Bull World Health Organ 2005;83:171-177. doi: org/10.1590/S0042-96862005000300009

Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19:335-351. doi: 10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z

Mihajlović J, Pechlivanoglou P, Miladinov-Mikov M, Zivković S, Postma MJ. Cancer incidence and mortality in Serbia 1999-2009. BMC Cancer. 2013;13:18. doi: 10.1186/1471-2407-13-18

World Health Organization. WHO report on the global tobacco epidemic, 2025: warning about the dangers of tobacco. Geneva, Switzerland: World Health Organization; 2025. Available from: https://www.who.int/publications/i/item/9789240112063, accessed [27 September 2025].

World Health Organization. World Health Organization 2025 data. Serbia [Country overview]. Geneva, Switzerland: World Health Organization; 2025. Available from: https://www.who.int/, accessed [27 September 2025].

Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. Eur Urol. 2016;70(3):458-466. doi: 10.1016/j.eururo.2015.06.042

Boström PJ, Alkhateeb S, Trottier G, Athanasopoulos PZ, Mirtti T, Kortekangas H, et al. Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer. BJU Int. 2012;109(1):70-76. doi: 10.1111/j.1464-410X.2011.10371.x

Teoh JY, Huang J, Ko WY, Lok V, Choi P, Ng CF, et al. Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. Eur Urol. 2020;78(6):893-906. doi: 10.1016/j.eururo.2020.09.006

Burge F, Kockelbergh R. Closing the Gender Gap: Can We Improve Bladder Cancer Survival in Women? - A Systematic Review of Diagnosis, Treatment and Outcomes. Urol Int. 2016;97(4):373-379. doi: 10.1159/000449256

Cohn JA, Vekhter B, Lyttle C, Steinberg GD, Large MC. Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation. Cancer. 2014;120(4):555-561. doi: 10.1002/cncr.28416

Toren P, Wilkins A, Patel K, Burley A, Gris T, Kockelbergh R, et al. The sex gap in bladder cancer survival - a missing link in bladder cancer care? Nat Rev Urol. 2024;21(3):181-192. doi: 10.1038/s41585-023-00806-2

Zlatev DV, Altobelli E, Liao JC. Advances in imaging technologies in the evaluation of high-grade bladder cancer. Urol Clin North Am. 2015;42(2):147-157, vii. doi: 10.1016/j.ucl.2015.01.001

Godlewski D, Czech S, Szpara J, Bartusik-Aebisher D, Aebisher D. A Narrative Review of Current Advances and Future Changes Regarding Bladder Cancer Treatment. Uro. 2025;5(2):11. doi: 10.3390/uro5020011

Liu S, Yang T, Na R, Hu M, Zhang L, Fu Y, et al. The impact of female gender on bladder cancer-specific death risk after radical cystectomy: a meta-analysis of 27,912 patients. Int Urol Nephrol. 2015;47(6):951-958. doi: 10.1007/s11255-015-0980-6

Soave A, Dahlem R, Hansen J, Weisbach L, Minner S, Engel O, et al. Gender-specific outcomes of bladder cancer patients: a stage-specific analysis in a contemporary, homogenous radical cystectomy cohort. Eur J Surg Oncol. 2015;41(3):368-377. doi: 10.1016/j.ejso.2014.03.003

Ball KS, Hounsome L, Verne J, Kockelbergh R. Non-transitional cell carcinoma only partly explains adverse survival outcomes in females with T1–T4 bladder cancer: A summary of UK epidemiological data. Journal of Clinical Urology. 2017;10(1_suppl):14-18. doi:10.1177/2051415816679529

Krimphove MJ, Szymaniak J, Marchese M, Tully KH, D'Andrea D, Mossanen M, et al. Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. Eur Urol Focus. 2021;7(1):124-131. doi: 10.1016/j.euf.2019.06.001

de Jong JJ, Boormans JL, van Rhijn BWG, Seiler R, Boorjian SA, Konety B, et al. Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. Eur Urol Oncol. 2020;3(4):420-423. doi: 10.1016/j.euo.2020.02.010

Lin W, Pan X, Zhang C, Ye B, Song J. Impact of Age at Diagnosis of Bladder Cancer on Survival: A Surveillance, Epidemiology, and End Results-Based Study 2004-2015. Cancer Control. 2023;30:10732748231152322. doi: 10.1177/10732748231152322

Luzzago S, Knipper S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, et al. Effect of Age on Cancer-specific Mortality in Patients With Urothelial Carcinoma of the Urinary Bladder: A Population-based Competing-risks Analysis Across Disease Stages. Am J Clin Oncol. 2020;43(12):880-888. doi: 10.1097/COC.0000000000000766

Yang Y, Cheng Z, Jia X, Shi N, Xia Z, Zhang W, et al. Mortality trends of bladder cancer in China from 1991 to 2015: an age-period-cohort analysis. Cancer Manag Res. 2019;11:3043-3051. doi: 10.2147/CMAR.S189220

Published
2025/11/30
Section
ORIGINAL ARTICLE